アブストラクト
| Title | 内分泌学ハイライト No. 1 免疫チェックポイント阻害薬と内分泌性免疫関連有害事象について |
|---|---|
| Subtitle | ミニレビュー |
| Authors | 諏訪内浩紹 |
| Authors (kana) | |
| Organization | 東京医科大学病院糖尿病・代謝・内分泌内科 |
| Journal | 東京医科大学雑誌 |
| Volume | 78 |
| Number | 2 |
| Page | 167-170 |
| Year/Month | 2020 / 4 |
| Article | 報告 |
| Publisher | 東京医科大学医学会 |
| Abstract | [要旨] 免疫チェックポイント阻害薬(Immune Checkpoint Inhibitor : CPI)は癌免疫療法として悪性腫瘍に使用されるようになった. 従来の抗がん剤に耐性が生じた癌に対し, PD-1やCTLA-4などの免疫チェックポイントを阻害する方法は癌治療を大きく変えている. 一方で, CPIは, 腫瘍効果以外に肝臓, 内分泌臓器, 消化管などの全身の臓器で自己免疫機序の有害事象が発生させ, これらは免疫関連有害事象(immune-related Adverse Events : irAE)と総称される. 内分泌irAEとしては, 1型糖尿病, 甲状腺機能異常症, 副甲状腺機能低下症, 副腎機能低下症, 下垂体機能低下症などが報告されており, 東京医科大学病院でも複数の症例を経験している. これらは早急に診断を行い適切な治療を行う必要がある. 本レビューでは, 内分泌irAE の臨床的特徴と病態を詳しく解説する. |
| Practice | 医学総合 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Azoury SC, Straughan DM, Shukla V : Immune Checkpoint Inhibitors for Cancer Therapy : Clinical Efficacy and Safety. Curr Cancer Drug Targets 15 : 452-462, 2015
- 2) Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA : Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241 : 180-205, 2011
- 3) Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al : Incidence of Endo-crine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens : A System-atic Review and Meta-analysis. JAMA Oncol 4 : 173-182, 2018
- 4) Byun DJ, Wolchok JD, Rosenberg LM, Girotra M : Cancer immunotherapy-immune checkpoint block-ade and associated endocrinopathies. Nat Rev Endocrinol 13 : 195-207, 2017
- 5) Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, et al : Patients With Antithy-roid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab : A Prospective Study. J Endocr Soc 2 : 241-251, 2018
残りの10件を表示する
- 6) McMillen B, Dhillon MS, Yong-Yow S : A rare case of thyroid storm. BMJ Case Rep : 10. 1136/bcr2016-214603, 2016
- 7) Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al : Antibody-mediated thyroid dys-function during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28 : 583-589, 2017
- 8) Kotwal A, Kottschade L, Ryder M : PD-L1 Inhibi-tor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid, 2020
- 9) Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al : The programmed death-1(PD-1)pathway regulates autoimmune diabetes in nonobese diabetic(NOD)mice. J Exp Med 198 : 63-69, 2003
- 10) Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, et al : SOCIETY FOR ENDO-CRINOLOGY ENDOCRINE EMERGENCY GUIDANCE : Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7 : G1-g7, 2018
- 11) Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al : Collateral Damage : Insulin-Dependent Diabetes Induced With Check-point Inhibitors. Diabetes 67 : 1471-1480, 2018
- 12) Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, et al : Hypophysitis Second-ary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade : Insights into Pathogenesis from an Autopsy Series. Am J Pathol 186 : 3225-3235, 2016
- 13) Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J, et al : Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. J Clin Endocri-nol Metab 103 : 365-369, 2018
- 14) Dillard T, Yedinak CG, Alumkal J, Fleseriu M : Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis : serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13 : 29-38, 2010
- 15) Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, et al : Evaluation of Readmin-istration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol, 2019
